Research on the care and experience of people living with cancer. Covers survivorship, supportive care, diagnosis in low-resource settings, immunotherapy trials, and quality of life.
A phase 2 study found that the combination of belzutifan and cabozantinib produced a confirmed objective response rate of 70% among patients with advanced clear-cell renal cell carcinoma. The treatment was well-tolerated, with manageable serious adverse events.
The new NCCN Guidelines for Patients: Genetic Testing for Hereditary Breast, Ovarian, Pancreatic, and Prostate Cancer provide evidence-based recommendations for assessing and testing for inherited genetic mutations. The resource aims to inform individuals about their cancer risks based on personal or family history.
The University Hospitals fundraising campaign, Because of You, has received over $1.5 billion in community support towards its ambitious $2 billion goal. This milestone marks a significant commitment to advancing healthcare services and care for patients across the country.
According to UTHealth Houston research, adolescent and young adult men with cancer have a slightly elevated risk of having preterm birth and children with low birth weight. However, the likelihood of live birth was highest for fathers who had thyroid cancer and lowest for those with gastrointestinal cancer.
The study, published in the Journal of Clinical Oncology, showed no significant difference in patient survival between two-drug and three-drug chemotherapy regimens. The researchers found that the three-drug regimen may increase toxicity but could be a viable option for specific patients with certain types of biliary tract cancers.
The phase 3 KATHERINE clinical trial found trastuzumab emtansine to be an effective adjuvant treatment for high-risk HER2-positive breast cancer patients, reducing the risk of death or invasive disease by 46% and improving survival. The study showed consistent benefits across patient subgroups, supporting T-DM1 as a new standard of care.
A new trial has found that patients with suspected invasive bladder cancer treated with initial MRI imaging and biopsy are faster than those assessed with TURBT alone. The BladderPath trial showed a median time of 53 days from referral to correct treatment, compared to 98 days for usual care.
Researchers developed a system to monitor tumor-informed circulating tumor DNA (ctDNA) after comprehensive genomic profiling (CGP), enabling accurate prediction of patient outcomes. The study showed that this approach can be effectively used in conjunction with CGP data to predict cancer relapse and treatment response, improving person...
A recent population-based study indicates that among children with cancer, those with obesity at the time of diagnosis may face an elevated risk of dying. The study found a significant negative impact of obesity on prognosis, particularly in patients with acute lymphoblastic leukemia and brain tumors.
The book highlights innovative strategies for addressing Latino cancer disparities, including risk assessment, prevention, screening, detection, diagnosis, treatment, survivorship, and policy. It also shares model programs and resources to shape future efforts to address cancer among Latinos and all people.
The National Comprehensive Cancer Network (NCCN) has joined a two-day meeting in Riyadh, Saudi Arabia, to review updated NCCN Clinical Practice Guidelines for the MENA region. The guidelines provide evidence-based expert consensus-driven recommendations for cancer prevention, screening, treatment, and supportive care, tailored for uniq...
A novel patient-derived organoid library of tongue cancer tissue samples reveals new insights into chemoresistance mechanisms, highlighting the importance of autophagy and cholesterol biosynthesis pathways. The research also identifies potential drug targets for overcoming chemotherapy resistance in tongue cancer.
A nationwide cohort study in Korea found that postdiagnosis weight gain is associated with an increased risk of heart failure after breast cancer development. Effective weight intervention can protect cardiovascular health, particularly within the first few years after diagnosis.
Researchers discovered a key role for neutrophils in cancer cell colonization of abdominal fat through the release of DNA webs called NETs. Additionally, a new biomarker study found that dose-dense chemotherapy improved disease-free survival by 20% and overall survival by 15% for women with early-stage ER-positive breast cancer.
A multi-institutional study led by Mayo Clinic researchers has improved the accuracy of genetic testing for BRCA2 variants, enabling precise risk assessments and personalized treatment plans. The findings will aid in identifying patients who may benefit from targeted therapies such as PARP inhibitors.
A recent study found that cancer patients who traveled to local or national healthcare centers had higher five-year survival rates compared to those who remained in their residential cities. The study highlights critical disparities in healthcare resource allocation and quality across regions.
A new study has identified macrophage activity as a key predictor of which skin cancer patients are most likely to respond to immunotherapy. The findings aim to improve personalized medicine for cancer patients and enable clinicians to select effective treatments, reducing side effects and costs.
A large international study of GLP1-RA users and dipeptidyl peptidase-4 inhibitors (DPP-4i) found no evidence that GLP1-RA use is associated with an increased risk of thyroid cancer. The study, published in the Thyroid journal, analyzed data from 92,497 GLP1-RA users and 2,484,408 DPP-4i users.
A University of Cincinnati Cancer Center study identifies microRNA miR-205 as a promising new target to overcome breast cancer treatment resistance and improve outcomes. The research found that boosting levels of miR-205 could block the production of MED1, a protein responsible for treatment resistance, and improve treatment outcomes.
The alliance aims to generate evidence supporting national guideline inclusion and healthcare provider adoption of Myriad's Precise MRD test. The studies will explore the test's utility in breast, gastrointestinal, genitourinary and gynecological cancers.
Weill Cornell Medicine has received a $2.3 million CDC grant to enhance care coordination for young breast cancer survivors, focusing on racially and socio-economically diverse groups to reduce symptom burden and improve survival outcomes.
Researchers analyzed data from over 700 patients with kidney injury and found that glucarpidase treatment improved kidney recovery rates. Glucarpidase rapidly clears methotrexate from the blood, reducing the risk of kidney toxicity.
A new study found that nearly half of high-risk prostate cancer patients have metastatic disease when evaluated with advanced PSMA-PET imaging, suggesting traditional imaging may underestimate cancer spread. This challenge the interpretation of previous studies like EMBARK trial, and support the inclusion of PSMA-PET for patient select...
Two studies suggest that psilocybin-assisted psychotherapy can improve mental health outcomes for patients with cancer and alcohol use disorder, reducing symptoms of anxiety, depression, and obsessive thoughts, while also promoting lasting personality changes.
A new study published in Nature Medicine shows that AI-based models can accurately identify ovarian cancer in ultrasound images, achieving an accuracy rate of 86.3%. The models also reduce the need for expert referrals and misdiagnosis rates by 63% and 18%, respectively.
A new study by Katherine Alexander and Shelley Berger has found a possible source of variability in cancer treatment response in clear cell renal cell carcinoma (ccRCC). The researchers identified two distinct patterns of nuclear speckles in kidney tumors, which may correlate with patient outcomes.
A nationwide cross-sectional study found sepsis incidence and mortality rates among hospitalized non-child cancer patients in China rose significantly, with higher rates observed in older patients.
Researchers have identified three distinct subtypes of osteosarcoma using advanced mathematical modeling and machine learning. This breakthrough could transform clinical trials and patient care by enabling targeted treatment personalized to individual cancer subtypes.
A Phase III clinical trial found that stereotactic body radiotherapy (SBRT) added to sorafenib improved progression-free survival and overall survival in patients with locally advanced hepatocellular carcinoma, particularly those with macrovascular invasion. The study also showed improvements in quality of life for these patients.
A Norwegian study investigates the relationship between volunteers and patients, revealing that intimate disclosures can create an imbalanced dynamic. The researchers emphasize the importance of maintaining professional boundaries to avoid emotional burnout and ensure effective support.
The new therapy significantly improves three-year disease-free survival for children with B-ALL, with 96% being disease-free for at least three years. Blinatumomab is now being used in most patients due to its practice-changing breakthrough, offering improved quality of life and reduced side effects.
Researchers at MD Anderson Cancer Center have made significant breakthroughs in smoking cessation treatments, with a study finding that varenicline plus counseling is the most effective treatment for individuals with major depressive disorder. Additionally, a new radiotherapy technique demonstrates effectiveness in treating metastatic ...
A team of researchers from Wilmot Cancer Institute and University of Rochester Medical Center investigate how social networks influence cancer patients' treatment decisions. They plan to analyze 300 local individuals aged 65+ with advanced cancer, tracking their networks and decision-making processes.
Scientists at the University of Plymouth are creating a humanised meningioma model to study interactions between immune cells and tumour cells, enabling the development of effective therapies for NF2-related schwannomatosis. The model will be made available worldwide to test new treatments and reduce clinical trial delays.
Researchers have developed a new scan that lights up aggressive cancer tumors, allowing doctors to target and treat cancer more effectively. The scan uses a radiotracer to show treatment-resistant tumours on PET scans, giving patients alternative options for better survival rates.
A new study explores whether CBD can reduce scan-related anxiety in advanced breast cancer patients, finding it was safe but did not significantly change anxiety levels. However, participants who consumed CBD experienced lower anxiety levels after treatment.
A new blood test developed by RMIT University researchers could help personalize cancer treatments, making them safer and more effective. The test assesses how well different nanomedicines target cancer cells in the blood of leukemia patients, allowing for more tailored therapies.
A phase 2 study conducted by Mayo Clinic found that 56% of participants were alive after 12 months, with a median overall survival of 13.1 months. The treatment, which combines short-course hypofractionated proton beam therapy with advanced imaging techniques, was more effective in patients over 65 with favorable tumor genetics.
Adding camrelizumab to neoadjuvant chemotherapy significantly improved pathological complete response in patients with early or locally advanced triple-negative breast cancer. The treatment showed substantial benefits, leading researchers to explore its potential as a neoadjuvant strategy.
Researchers at Osaka Metropolitan University developed a new technique for head and neck reconstruction that achieves 100% success rate in high-risk patients. The pedicled latissimus dorsi flap technique provides a reliable, fast, and minimally invasive option for complex tissue defects.
Researchers analyzed data from 11,797 adults with advanced solid cancers and found no difference in mortality rates during the shortage period. Prescription rates for cisplatin and carboplatin fell less than three percent overall, with alternative therapies helping mitigate the crisis.
A new study found that a low omega-6, high omega-3 diet with fish oil supplements significantly reduced prostate cancer cell proliferation in men. The findings suggest that dietary changes could potentially delay or prevent the need for more aggressive treatments.
A new study reveals that social risks like food insecurity and housing instability impede patients' ability to receive routine cancer screenings, even when they have access to healthcare. The research highlights the need for health providers to take a more holistic approach to patient care to address these challenges.
A study published in Journal of Pain and Symptom Management found that Reiki therapy resulted in clinically significant improvements in pain, fatigue, anxiety, nausea, and well-being among outpatients with cancer. The study involved 392 Reiki sessions for 268 unique patients, showing a mean improvement of 1.78 in pain and 2.09 in anxiety.
Glioblastoma brain tumors synchronize their growth with the daily release of steroid hormones like cortisol, according to new research. Blocking these signals slows tumor growth and disease progression in animal models.
Researchers developed a deep learning model that classifies pancreatic cancer into molecular subtypes using histopathology images, achieving high accuracy and rapid turnaround time. The AI tool has the potential to improve patient outcomes by enabling timely and tailored treatment strategies.
The PATINA study demonstrates that palbociclib improves progression-free survival (PFS) in patients with HR+, HER2+ metastatic breast cancer, with a median PFS of 44.3 months. This represents an extension in median PFS of over 15 months compared to anti-HER2 therapy and endocrine therapy alone.
The PROSPECT-Lung trial evaluates the role of immunotherapy before and after surgery in resectable non-small cell lung cancer patients. The trial aims to determine whether adding immune checkpoint inhibitors to standard chemotherapy improves survival outcomes.
A new DNA sequencing test called AR-ctDETECT has been found to distinguish between patients with poor and favorable prognoses in advanced prostate cancer. The test identified circulating tumor DNA in 59% of patients and showed that detectable ctDNA was associated with worse overall survival.
The American College of Surgeons Geriatric Surgery Verification program significantly decreases hospital stays among older cancer patients, increasing their independence and likelihood of discharge home. The program addresses the unique needs of older adults undergoing major abdominal oncologic procedures.
The collaboration aims to evaluate the potential of AMB-066 as a first-in-class treatment option for patients with colorectal cancer and minimal residual disease. MD Anderson researchers have identified a potential opportunity for AMB-066 to effectively treat MRD-positive CRC, based on robust preclinical data.
Researchers aim to improve treatment response in patients with clear cell renal cell carcinoma by reprogramming tumor cells into immune cells that recognize and kill cancer cells. This approach combines checkpoint inhibitors to enhance the immune response.
Researchers at UCLA Health presented several breakthroughs at the San Antonio Breast Cancer Symposium, including improved survival rates for advanced breast cancer patients who receive trastuzumab deruxtecan (T-DXd), a novel ADC. Additionally, new genomic testing and circulating tumor DNA analysis may help identify high-risk patients a...
A phase 3 trial shows that autologous stem cell transplants do not improve survival for mantle cell lymphoma patients in complete remission and undetectable minimal residual disease. Patients who remain MRD-positive after induction may benefit from ASCT, but longer follow-up is needed to confirm these findings.
A study suggests that low doses of the commonly prescribed hair loss treatment minoxidil are safe and effective for regrowing hair in most breast cancer patients. The researchers found that all participants who took a low dose of oral minoxidil saw improvements in hair growth or stabilization within three to six months.
Two clinical trials testing loncastuximab tesirine showed promising results in patients with high-risk forms of follicular lymphoma and marginal zone lymphoma. The treatment achieved impressive response rates, including a 70% complete response rate for marginal zone lymphoma and an overall response rate of 97% for follicular lymphoma.
Experts discuss strategies and best practices for sharing accurate, evidence-based health information with patients and caregivers. The event aimed to empower people with cancer to make informed choices about their care.
A team of UNC-Chapel Hill researchers will develop an oncology health learning system using AI-ready data to generate real-time identification of new cancer cases and support personalized treatments. The project aims to improve cancer diagnosis, care equity, and quality by creating accessible tools for health providers.
A phase 3 study demonstrated nearly 75% complete cancer remission in patients with high-risk bladder cancer unresponsive to BCG therapy. The novel treatment, cretostimogene grenadenorepvec, was well-tolerated and did not require bladder removal surgery.
A new ASTRO survey finds that prior authorization delays lead to treatment interruptions, hospitalizations, and patient deaths. The problem is worsening, with patients experiencing longer treatment delays than during the COVID-19 pandemic.